A phase III, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’xx quadrivalent, inactivated, split virion, seasonal influenza vaccine candidate, GSK2282512 (FLU Q-QIV), administered intramuscularly in healthy children 3 to 8 years of age.